Bayer AG

Latest Bayer AG News and Updates

  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron’s Dupixent Approved for Atopic Dermatitis

    In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

    By Daniel Collins
  • uploads///ZTS industry stats
    Consumer

    Must-know trends that drive Zoetis’ growth

    Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.

    By Samantha Nielson
  • Healthcare

    Third Point believes Amgen’s acquisitions should have done more

    Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

    By Samantha Nielson
  • uploads///GBUs Q  performance
    Company & Industry Overviews

    Sanofi’s Organizational Restructuring: Investor Insights

    On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.

    By Sarah Collins
  • uploads///Cabometyx
    Company & Industry Overviews

    Cabometyx Could Be Exelixis’s Long-Term Growth Driver

    In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.

    By Daniel Collins
  • uploads///Cardiovascular
    Company & Industry Overviews

    How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017

    In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///LOE
    Company & Industry Overviews

    How Pfizer’s Peri-LOE Products Performed in 2017

    Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.

    By Daniel Collins
  • uploads///Sutent
    Company & Industry Overviews

    Pfizer’s Sutent Generated Higher Revenues in 4Q17

    In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.

    By Daniel Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Updates after Sanofi’s Bioverativ Announcement

    In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

    By Sarah Collins
  • uploads///Interferons
    Company & Industry Overviews

    How Biogen’s Biosimilars and Interferons Performed in 4Q17

    In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Eloctate
    Company & Industry Overviews

    How Is Bioverativ’s Eloctate Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    How Is Roche’s Hemlibra Positioned for 2018?

    Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

    By Daniel Collins
  • uploads///hemophilia
    Company & Industry Overviews

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

    By Daniel Collins
  • uploads///Opsumit
    Company & Industry Overviews

    How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17

    In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

    By Daniel Collins
  • uploads///Oral care
    Company & Industry Overviews

    How JNJ’s Consumer Products Performed in 3Q17

    In 3Q17, Johnson & Johnson’s (JNJ) oral care products generated revenues of $382 million, which reflected a 3% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Promacta Votrient jakavi
    Company & Industry Overviews

    How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17

    In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Lucentis
    Company & Industry Overviews

    How Is Novartis’s Lucentis Positioned after 1H17?

    In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///BioMarins Developmental
    Company & Industry Overviews

    BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver

    After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.

    By Daniel Collins
  • uploads///Alprolix Eloctate
    Company & Industry Overviews

    How Are Bioverativ’s Key Drugs Positioned after 2Q17?

    In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

    By Daniel Collins
  • uploads///IM
    Company & Industry Overviews

    A Post-2Q17 Look at Pfizer’s Internal Medicines

    In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Orenitram Unituxin
    Company & Industry Overviews

    How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?

    In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Vectibix revenues
    Company & Industry Overviews

    What We May See from Amgen’s Vectibix in 2017

    Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Dupixent Could Substantially Drive Regeneron’s Growth

    In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

    By Daniel Collins
  • uploads///Internal Medicine
    Company & Industry Overviews

    How Pfizer’s Internal Medicines Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise.

    By Daniel Collins
  • uploads///Animal Health Revenues
    Company & Industry Overviews

    How Merck’s Animal Health Business Is Expected to Perform in 2017

    In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.

    By Daniel Collins
  • uploads///Portfolio Breakdown of the AXEAX
    Fund Managers

    Sector Composition of the Columbia European Equity Fund

    The Columbia European Equity Fund Class A (AXEAX) invests in “equity securities of European companies that are believed to offer growth potential.”

    By David Ashworth
  • uploads///Portfolio Breakdown of the AXEAX
    Fund Managers

    Sector Composition Changes in AXEAX until 1Q16

    AXEAX was invested across 69 holdings as of March 2016, seven more than a quarter ago. It was managing assets worth $515.6 million as of March.

    By David Ashworth
  • uploads///USAA International Fund Vs Peers
    Company & Industry Overviews

    How Are the USAA International Fund’s Metrics?

    From a purely NAV (net asset value) return standpoint, the USIFX did not have a notable showing in either the one-year period until February 29, 2016, or in 2015.

    By David Ashworth
  • Company & Industry Overviews

    ARTIX: How Is 2016 Looking so Far for the Fund?

    The Artisan International Fund – Investor Class (ARTIX) has been in existence since December 1995.

    By David Ashworth
  • uploads///Portfolio Break down of the AXEAX
    Macroeconomic Analysis

    How the Columbia European Equity Fund Fared until October

    As of the September portfolio of the Columbia European Equity Fund, the top ten equity holdings included Novartis, Roche Holding, and Prudential Financial.

    By David Ashworth
  • uploads///ARTIXs Top Ten Invested Geographies
    Macroeconomic Analysis

    Essentials of the Artisan International Fund (ARTIX)

    The Artisan International Fund (ARTIX) requires a minimum initial investment of $1,000. There’s no minimum or specific amount needed to add to an account.

    By David Ashworth
  • uploads///Portfolio Break down of the AXEAX
    Macroeconomic Analysis

    The Columbia European Equity Fund Class A (AXEAX): Historical Overview

    The Columbia European Equity Fund seeks capital appreciation by investing in “equity securities of European companies that…offer growth potential.”

    By David Ashworth
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.